Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.

Tuberculosis (TB) is a global public health problem exacerbated by the HIV epidemic.Here we evaluate a candidate TB vaccine, MVA85A, in a Phase I study in HIV-infected adults in Senegal.24 patients were enrolled: Group 1:12, antiretroviral therapy (ART) naı ¨ve, adults, with CD4 counts .300and HIV RNA load ,100 000 copies/ml.Group 2:12 adults, stable on ART, with CD4 counts .300,and an undetectable HIV RNA load.Safety was evaluated by occurrence of local and systemic adverse events (AEs) and by monitoring of CD4 count, HIV RNA load, haematology and biochemistry.Immunogenicity was evaluated by ex-vivo interferon-gamma ELISpot assay.87.7% of AEs were mild; 11.6% were moderate; and 0.7% were severe.29.2% of AEs were systemic; 70.8% were expected local AEs.There were no vaccine-related Serious Adverse Events (SAEs) or clinically significant effects on HIV RNA load or CD4 count.In ART naive subjects, the first MVA85A immunisation induced a significant immune response at 1 and 4 weeks post-immunisation, which contracted to baseline by 12 weeks.Durability of immunogenicity in subjects on ART persisted out to 24 weeks post-vaccination.A second dose of MVA85A at 12 months enhanced immunogenicity in ART naı ¨ve subjects.Subjects on ART had higher responses after the first vaccination compared with ART naı ¨ve subjects; responses were comparable after 2 immunisations.In conclusion, MVA85A is well-tolerated and immunogenic in HIV-infected subjects in Senegal.A two dose regimen in ART naı ¨ve subjects is comparable in immunogenicity to a single dose in subjects on ART.Clinicaltrials.govtrial identifier NCT00731471.

Abstract licence: CC BY

1. 12.
   Corrected

   MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques · 2009

34 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.